Illumina and Siemens Healthcare Diagnostics said today that they will co-develop molecular diagnostic tests on Illumina's MiSeq sequencer.

The companies plan to initially convert Siemens' Trugene HIV genotyping assay, which is currently run on Siemens' Sanger-based OpenGene sequencing system, to the MiSeq.

Eventually, the companies will adapt all of Siemens' HIV tests for the MiSeq, as well as other infectious disease assays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.